The Case For A Long-Term Editas Position

Editas Medicine (NASDAQ:EDIT) is an early-stage gene-editing company that mainly focuses on CRISPR technology. If the experiment works, CRISPR will allow medical professionals to snip out the patient's faulty DNA and replace it with healthy DNA. There's also the possibility of this type of technology being used to improve even healthy people via this process.

The company's objective is to develop transformative genomic medicines to treat a range of serious diseases.

Original source

Add comment

Please Sign in to be able to leave comments.